sRANKL

AcronymDefinition
sRANKLSoluble Receptor Activator of NFkappaB (Nuclear Factor Kappa B) Ligand
References in periodicals archive ?
BMMs (5 x [10.sup.4] cells/well) were incubated with [alpha]-MEM containing 10% FBS, M-CSF (30 ng/ml), sRANKL (100 ng/ml), and different concentrations of liensinine or nuciferine for 5 days.
BMMs (5 x [10.sup.4] cells/well) were seeded into an Osteo assay plate (Corning, NY) and cultured with [alpha]-MEM containing 10% FBS, M-CSF (30 ng/ml), and sRANKL (100 ng/ml) for 5 days.
Circulating levels of sRANKL were significantly decreased after TNFi (p = 0.0085; Table 4), leading to decreased sRANKL/OPG ratio (p = 0.0031).
Patients under TNFi had reduced levels of sRANKL, sRANKL/OPG, CTX-I, and P1NP, suggesting a decrease in OC activity and a return to balanced coupling of bone resorption and bone formation.
Bone mineral density (BMD), bone-alkaline phosphatase (b-ALP), collagen C-telopeptides (CTX), osteoprotegerin (OPG) and soluble receptor activator of NFKB ligand (sRANKL) were assessed.
An elevated level of plasma sRANKL leads to bone resorption and loss, explained Dr.
To investigate the effectiveness of different anticoagulants on stabilizing sRANKL and OPG activity, plasma/ serum was separated at 15, 30, and 60 min after venesection by centrifugation at 1814g for 10 min at 4 [degrees]C.
Serum Concentration of OPG and sRANKL. In AS patients, the OPG levels were significantly higher compared to those of the control group (Table 2).
Ivanovska, "Involvement of soluble receptor activator of nuclear factor-[kappa]B ligand (sRANKL) in collagenase-induced murine osteoarthritis and human osteoarthritis," Rheumatology International, vol.
PMR'de osteoprotegenin (OPG) ve sRANKL duzeyi artmis olarak bulunmus ve bu durumun kemik dongusunu bozabilecegi iddia edilmistir (64).
OPG and sRANKL serum concentrations in osteopenia, postmenopausal women after 2-year genistein administration.
builds upon a longstanding relationship between ALPCO and Biomedica Gruppe, premier developer and manufacturer of immunoassays for the bone metabolism field, including the Osteoprotegerin (OPG), sRANKL, DKK-1 and Cathepsin K ELISAs.